Pocenbrodib is Pathos’ first clinical-stage asset in its pipeline. "The clinical promise of pocenbrodib, our potential best-in-class CBP/p300 inhibitor, lies not only in its remarkable efficacy in ...
Tempus AI Inc. (NASDAQ:TEM) during the first quarter secured a multi-million dollar deal to build “the world’s largest foundation model for oncology.” “And this is big for a few reasons,” said Tempus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback